U.S., Dec. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07292012) titled 'Efficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's Disease' on Nov. 24.

Brief Summary: Efficacy of Mirikizumab to achieve transmural healing in patients with Crohn's Disease

Study Start Date: Jan., 2026

Study Type: INTERVENTIONAL

Condition: Crohn Disease (CD)

Intervention: DRUG: Mirikizumab - IV

Mirikizumab induction with IV infusions (900 mg) at week 0, week 4 and week 8.

DRUG: Mirikizumab - SC

SC injections (300 mg) at W12 and every 4 weeks For clinical responders and non-responders

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Groupe d'Etude Therapeutique des Affections Inflammatoires Dige...